基于组织学的人工智能生物标志物预测胰腺癌辅助化疗获益
本研究利用231例接受辅助mFOLFIRINOX或GEM的胰腺导管腺癌患者全切片图像训练深度学习模型,构建PANCprAId生物标志物,并在PRODIGE-24/CCTG PA6随机试验(n=313)中外部验证。
要点
- PANCprAId可预测胰腺癌辅助GEM与mFOLFIRINOX的相对获益。
- 预测敏感性分别与不同的上皮和间质特征相关。
核心结论
- 基于组织学的深度学习可衍生预测胰腺导管腺癌辅助GEM与mFOLFIRINOX相对获益的生物标志物。
研究设计与样本
- 回顾性多中心系列231例接受治愈性胰腺切除术并辅助mFOLFIRINOX(n=54)或GEM(n=177)的患者全切片图像用于训练方案特异性组织学模型。
- 外部验证在随机PRODIGE-24/CCTG PA6试验(n=313)中进行。
主要发现
- 预测对每种方案的敏感性与不同的上皮和间质特征相关。
临床怎么用
- 该生物标志物有望辅助选择胰腺导管腺癌术后辅助化疗方案(GEM vs mFOLFIRINOX)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The choice of adjuvant chemotherapy in pancreatic ductal adenocarcinoma (PDAC) is mainly guided by patients' general condition. We hypothesized that tumor morphology may predict differential treatment benefit and tested whether deep learning applied to histology images could derive a biomarker of relative benefit from gemcitabine (GEM) versus modified FOLFIRINOX (mFOLFIRINOX) in resected PDAC. PATIENTS AND METHODS: Standard whole-slide images from a retrospective multicentric series of 231 patients who underwent curative-intent pancreatectomy and received adjuvant mFOLFIRINOX (n = 54) or GEM (n = 177) were used to train regimen-specific histology models on disease-free survival (DFS), which were then combined into PANCprAId, a biomarker estimating personalized relative benefit from adjuvant GEM versus mFOLFIRINOX. External validation was performed in the randomized PRODIGE-24/CCTG PA6 trial (n = 313). RESULTS: In PRODIGE-24/CCTG PA6, the treatment-specific histology scores used to construct PANCprAId stratified outcomes among patients treated with GEM (hazard ratio [HR], 1.69 [95% CI, 1.04 to 2.73]; P = .03) and mFOLFIRINOX (HR, 2.02 [95% CI, 1.4 to 3.0]; P < .001). When combined into PANCprAId, the biomarker identified subgroups with differential relative benefit from adjuvant GEM versus mFOLFIRINOX, with significant treatment interactions for DFS (interaction P = .003) and cancer-specific survival (interaction P = .001). Predicted sensitivity to each regimen was associated with distinct epithelial and stromal features. CONCLUSION: Histology-based deep learning can derive a predictive biomarker of relative benefit from adjuvant GEM versus mFOLFIRINOX in resected PDAC.
引用
- Beaufils A, De Martino J, Jiang X, et al. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. J Clin Oncol. 2026. PMID: 42507965. doi:10.1200/JCO-26-00327
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。